Patents Assigned to Valerion Therapeutics, LLC
-
Patent number: 10781433Abstract: In certain embodiments, the present disclosure provides compositions and methods for treating Lafora Disease.Type: GrantFiled: September 8, 2017Date of Patent: September 22, 2020Assignee: Valerion Therapeutics, LLCInventor: Dustin D. Armstrong
-
Patent number: 10781434Abstract: The present disclosure provides for compositions comprising a chimeric polypeptide comprising a polypeptide effective for treating glycogen storage disease and an internalizing moiety that promotes delivery into cells. In certain embodiments, the polypeptide effective for treating glycogen storage disease is an acid alpha-glucosidase (GAA), a laforin, an amyloglucosidase (AGL), a malin, or an alpha amylase. The present disclosure also provides for methods for decreasing glycogen accumulation in cells or for treating glycogen storage diseases, including Forbes-Cori Disease, Andersen Disease, von Gierke Disease, Pompe Disease, and Lafora Disease, comprising administering the chimeric polypeptide disclosed herein.Type: GrantFiled: February 11, 2019Date of Patent: September 22, 2020Assignee: Valerion Therapeutics, LLCInventor: Dustin D. Armstrong
-
Patent number: 10703824Abstract: The present disclosure provides antibodies and antigen-binding fragments capable of penetrating cells via an ENT transporter, such as humanized antibodies. The disclosure also provides conjugates comprising the antibodies or antigen-binding fragments and a heterologous agent. The disclosure further provides methods for making and using the antibodies, antigen-binding fragments and conjugates, including humanized antibodies.Type: GrantFiled: March 4, 2019Date of Patent: July 7, 2020Assignee: Valerion Therapeutics, LLCInventors: Dustin D. Armstrong, Jeffrey C. Way
-
Patent number: 10501554Abstract: In certain embodiments, the present disclosure provides compositions and methods for treating tumors and cancer.Type: GrantFiled: August 27, 2015Date of Patent: December 10, 2019Assignee: Valerion Therapeutics, LLCInventor: Dustin D. Armstrong
-
Patent number: 10238753Abstract: The disclosure provides novel conjugates comprising antisense oligonucleotides that hybridize to a DMPK transcript and a 3E10 antibody or binding fragment thereof. Also considered are these conjugates further comprising MBNL1 polypeptides. Methods of treating myotonic dystrophy using these conjugates and kits comprising these conjugates are also considered. Wherein the conjugates are suitable for delivery to muscle cells.Type: GrantFiled: March 30, 2017Date of Patent: March 26, 2019Assignee: Valerion Therapeutics, LLCInventor: Dustin D. Armstrong
-
Patent number: 10221250Abstract: The present disclosure provides antibodies and antigen-binding fragments capable of penetrating cells via an ENT transporter, such as humanized antibodies. The disclosure also provides conjugates comprising the antibodies or antigen-binding fragments and a heterologous agent. The disclosure further provides methods for making and using the antibodies, antigen-binding fragments and conjugates, including humanized antibodies.Type: GrantFiled: January 13, 2015Date of Patent: March 5, 2019Assignee: Valerion Therapeutics, LLCInventors: Dustin D. Armstrong, Jeffrey C. Way
-
Patent number: 10202591Abstract: The present disclosure provides for compositions comprising a chimeric polypeptide comprising a polypeptide effective for treating glycogen storage disease and an internalizing moiety that promotes delivery into cells. In certain embodiments, the polypeptide effective for treating glycogen storage disease is an acid alpha-glucosidase (GAA), a laforin, an amyloglucosidase (AGL), a malin, or an alpha amylase. The present disclosure also provides for methods for decreasing glycogen accumulation in cells or for treating glycogen storage diseases, including Forbes-Cori Disease, Andersen Disease, von Gierke Disease, Pompe Disease, and Lafora Disease, comprising administering the chimeric polypeptide disclosed herein.Type: GrantFiled: June 12, 2015Date of Patent: February 12, 2019Assignee: VALERION THERAPEUTICS, LLCInventor: Dustin D. Armstrong
-
Patent number: 10017581Abstract: In certain embodiments, the present disclosure provides compositions and methods for treating Pompe disease.Type: GrantFiled: February 20, 2014Date of Patent: July 10, 2018Assignee: Valerion Therapeutics, LLCInventors: Dustin D. Armstrong, Jeffrey C. Way
-
Patent number: 9610362Abstract: The disclosure provides novel conjugates comprising antisense oligonucleotides that hybridize to a DMPK transcript and a 3E10 antibody or binding fragment thereof. Also considered are these conjugates further comprising MBNL1 polypeptides. Methods of treating myotonic dystrophy using these conjugates and kits comprising these conjugates are also considered. Wherein the conjugates are suitable for delivery to muscle cells.Type: GrantFiled: March 14, 2013Date of Patent: April 4, 2017Assignee: Valerion Therapeutics, LLCInventor: Dustin D. Armstrong
-
Patent number: 9447394Abstract: The present invention provides chimeric polypeptides comprising myotubularin 1 (MTMI) polypeptides and an internalizing moiety, wherein, the moiety can be an antibody, and is preferably monoclonal antibody 3E10, a functional variant or a fragment thereof. One aspect of the present invention provides compositions comprising these chimeric polypeptides together with a pharmaceutically acceptable carrier, and optionally, a further therapeutic agent. Another aspect of the present invention provides methods of treating Myotubular Myopathy comprising administering the polypeptides or compositions comprising the polypeptides to a subject in need.Type: GrantFiled: September 12, 2014Date of Patent: September 20, 2016Assignee: Valerion Therapeutics, LLCInventor: Dustin D. Armstrong
-
Patent number: 9114178Abstract: In certain embodiments, the present invention provides compositions and methods for treating myotonic dystrophy.Type: GrantFiled: December 9, 2013Date of Patent: August 25, 2015Assignee: Valerion Therapeutics, LLCInventor: Dustin D. Armstrong
-
Publication number: 20150064181Abstract: The disclosure provides novel conjugates comprising antisense oligonucleotides that hybridize to a DMPK transcript and a 3E10 antibody or binding fragment thereof. Also considered are these conjugates further comprising MBNL1 polypeptides. Methods of treating myotonic dystrophy using these conjugates and kits comprising these conjugates are also considered. Wherein the conjugates are suitable for delivery to muscle cells.Type: ApplicationFiled: March 14, 2013Publication date: March 5, 2015Applicant: VALERION THERAPEUTICS, LLCInventor: Dustin D. Armstrong
-
Patent number: 8834866Abstract: The present invention provides chimeric polypeptides comprising myotubularin 1 (MTMI) polypeptides and an internalising moiety, wherein, the moiety can be an antibody, and is preferably monoclonal antibody 3E10, a functional variant or a fragment thereof. One aspect of the present invention provides compositions comprising these chimeric polypeptides together with a pharmaceutically acceptable carrier, and optionally, a further therapeutic agent. Another aspect of the present invention provides methods of treating Myotubular Myopathy comprising administering the polypeptides or compositions comprising the polypeptides to a subject in need.Type: GrantFiled: June 15, 2010Date of Patent: September 16, 2014Assignee: Valerion Therapeutics, LLCInventor: Dustin D. Armstrong
-
Publication number: 20140178377Abstract: In certain embodiments, the present invention provides compositions and methods for treating myotonic dystrophy.Type: ApplicationFiled: December 9, 2013Publication date: June 26, 2014Applicant: VALERION THERAPEUTICS, LLCInventor: Dustin D. Armstrong
-
Patent number: 8609615Abstract: In certain embodiments, the present invention provides compositions and methods for treating myotonic dystrophy.Type: GrantFiled: October 15, 2009Date of Patent: December 17, 2013Assignee: Valerion Therapeutics, LLCInventor: Dustin D. Armstrong